The London and Cambridge Life Sciences team advised Endomag on its $20 million Series D funding round led by Draper Esprit, to continue expanding access to new advanced breast surgery techniques enabled by Endomag’s products.
The round is the largest in the company’s history and was supported by existing investor Sussex Place Ventures, among others. The investment follows Draper Esprit’s initial lead in Endomag’s 2018 Series C round, bringing the company’s total funding to over $43 million.
Endomag technologies use non-invasive magnetic sensing to locate and stage breast cancer and have helped over 130,000 women across the world receive more precise and less invasive cancer treatment.
The Goodwin team was led by David Mardle, Adam Thatcher.
For additional details on the funding round, please read BusinessWeekly's coverage.